Long-term outcome of renal cell carcinoma in patients with HIV who undergo surgery

Abstract

Background People living with HIV (PLWH) have a higher risk for cancer compared to the general population. The prevalence of renal cell carcinoma (RCC) in PLWH has gradually increased in recent years, but relevant data on outcomes after surgery are scarce. We thus evaluated long-term outcomes after surgery in RCC patients with and without HIV. Methods This retrospective study included 67 patients with RCC, both HIV positive or negative, who underwent surgical treatment in our hospital between January 2012 and January 2021. Demographic details, clinical data, and cancer status were collected. We set the day of surgery as the baseline. The co-primary end points in this time-to-event analysis were overall survival and progression-free survival. We used a multivariate Cox model to compare the prognosis of PLWH and HIV-negative patients and present Kaplan–Meier curves for the co-primary end points. Results Of 261 consecutive patients, 18 patients who forwent treatment before surgery, 133 cases with incomplete data, 16 patients classified as clinical stage IV, 11 PLWH patients did not received antiretroviral therapy and 16 patients with metastasis were excluded from the main analysis. Of the remaining 67 patients, 33 individuals had HIV and the other 34 did not. The median overall survival was 74.9 months (95% confidence interval [CI] = 64.6 to 85.2) in PLWH and 96.4 months (95% CI = 90.0 to 102.9) in the HIV-negative group. Progression-free survival was 66.4 months (95% CI = 53.5 to 79.3) and 90.6 months (95% CI = 81.1 to 100.1), respectively. RCC patients with HIV who underwent surgery had a shorter survival time (hazard ratio [HR] = 2.8, 95% CI = 1.1 to 7.0, p = 0.016) and an increased incidence of tumor progression (HR = 2.7, 95% CI = 1.1 to 6.8, p = 0.028). Univariate and multivariate Cox regression analyses showed that a lower ratio of CD4+ T cells to CD8+ T cells (adjusted odds ratio = 0.092, 95% CI = 0.01 to 0.70, p = 0.022) was associated with worse survival among PLWH. Conclusion In this retrospective analysis of RCC patients who underwent surgery, PLWH had worse overall survival and shorter progression-free survival compared to HIV-negative cases.

The Efficacy and Safety of Tislelizumab as Adjuvant Treatment for Advanced or Metastatic Bladder Cancer in People Living With HIV: A Retrospective Multi-Center Study

“…Our team’s previous studies have confirmed that the survival of the PLWH with stage I to III renal carcinomas after surgery is worse than that of the general population. 39 The PLWH with UC is rarely reported previously; however, encouragingly, our study provided preliminary evidence that tislelizumab in PLWH with locally advanced or metastatic BCa can achieve similar efficacy and safety comparable to those of people with the same stage BCa but no HIV.…”

Expression of RNA-m6A-related genes correlates with the HIV latent reservoir level and the CD4+ and CD8+T cell profiles of patients with AIDS

“…The exposed, free HIV can then be eradicated with high doses of anti-HIV drugs, which also serve to induce the apoptosis and lysis of CD4 + T cells. Thus, the latent repository of HIV is exterminated as a result of cytopathy (22,23). However, this technology is not sufficiently developed for clinical application.…”

The association between the CD4/CD8 ratio and surgical site infection risk among HIV-positive adults: insights from a China hospital

“…A previous study found that when the CD4+ T lymphocyte count was consistently above 200 and the CD4/CD8 ratio was above 0.15, the risk of sepsis during abdominal surgery was reduced ( 27 ). Low ratios were associated with poorer survival in PLWH after analyzing 67 patients with right colon cancer (RCC) who underwent surgery ( 28 ). Moreover, this ratio not only predicts patient prognosis but can be used as a predictor of mortality in HIV-positive patients.…”